Key Highlights From the Annual Symposium of the American Society of Spine Radiology
March 23rd 2022In a recent video interview, Kevin J. Abrams, MD, discussed highlights from the recent 25th Annual Symposium of the American Society of Spine Radiology (ASSR), including lectures on imaging for spontaneous intracranial hypotension, the emergence of dynamic susceptibility contrast for MR perfusion and insights on the use of dual-energy computed tomography (CT) for diagnosing vertebral fractures.
Breast Imaging: Challenges and Opportunities in the Aftermath of the COVID-19 Pandemic
March 8th 2022In a recent video interview, Amy K. Patel, MD, discussed the aftereffects of delayed breast cancer screening due to the COVID-19 pandemic, keys for improving outreach to underserved communities, legislative wins and challenges, and coalition building to educate and encourage women to resume regular breast cancer screening exams.
Assessing and Implementing Artificial Intelligence in Radiology
February 21st 2022In a recent video interview, Nina Kottler, MD, discussed the promise of artificial intelligence (AI) for improving workflow efficiency for radiologists, keys to assessing AI vendors and change management principles for facilitating implementation of AI into one’s practice.
Essential Keys to Preventing Burnout in Radiology
February 18th 2022In a new video presentation, a neuroradiologist discusses steps that individual radiologists can take to reduce the risk of physician burnout as well as actions that group radiology practices can take to increase the engagement of their staff.
Challenging the IDR Process of the No Surprises Act
February 1st 2022In an exclusive video interview with Diagnostic Imaging, Josh Cooper, vice president of congressional affairs for the American College of Radiology (ACR), and Thomas Hoffman, vice president of legal for the ACR, discuss the ACR’s lawsuit over the IDR process of the No Surprises Act and the potential impact of the law on reimbursement and patient access to care.
Prostate Cancer: Integrating Newer Imaging Modalities Into Clinical Practice
January 31st 2022Interesting questions raised by a paper that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer and implications for integrating newer techniques into clinical practice.
Key Takeaways: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 24th 2022Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.
Presentation: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 20th 2022Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.
Background: 18F-Fluciclovine and 68Ga-PSMA-11 Imaging in Prostate Cancer
December 23rd 2021Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.